• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001).

作者信息

Villers A, Pommier P, Bataillard A, Fervers B, Bachaud J M, Berger N, Bertrand A F, Bouvier R, Brune D, Daver A, Fontaine E, Haillot O, Lagrange J L, Molinie V, Muratet J P, Pabot du Chatelard P, Peneau M, Prapotnich D, Ravery V, Richaud P, Rossi D, Soulie M

机构信息

CHRU Hôpital Huriez, Lille, France.

出版信息

Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S50-8. doi: 10.1038/sj.bjc.6601084.

DOI:10.1038/sj.bjc.6601084
PMID:12915903
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2753017/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/c7431890deea/89-6601084f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/40afc577e76f/89-6601084f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/6632989f2c15/89-6601084f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/03c30e86ea2c/89-6601084f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/7199d8b99ef3/89-6601084f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/bdf5074b994c/89-6601084f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/72ffdf73fad3/89-6601084f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/a85cea3019d3/89-6601084f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/6960248aacaa/89-6601084f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/c7431890deea/89-6601084f9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/40afc577e76f/89-6601084f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/6632989f2c15/89-6601084f2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/03c30e86ea2c/89-6601084f3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/7199d8b99ef3/89-6601084f4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/bdf5074b994c/89-6601084f5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/72ffdf73fad3/89-6601084f6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/a85cea3019d3/89-6601084f7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/6960248aacaa/89-6601084f8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b324/2753017/c7431890deea/89-6601084f9.jpg

相似文献

1
Summary of the Standards, Options and Recommendations for the management of patients with nonmetastatic prostate cancer (2001).非转移性前列腺癌患者管理的标准、选项及建议总结（2001年）
Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S50-8. doi: 10.1038/sj.bjc.6601084.
2
[Standards, options and recommendations for the management of prostate cancer: therapeutic decision criteria].
Bull Cancer. 2002 Jun;89(6):619-34.
3
Guidelines on the management of prostate cancer. A document for local expert groups in the United Kingdom preparing prostate management policy documents.
BJU Int. 1999 Dec;84(9):987-1014.
4
Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.局限性前列腺癌的治疗：根据其自然病程（通常进展相对缓慢），可选择观察等待、手术或放射治疗。
Prescrire Int. 2012 Oct;21(131):242-8.
5
Summary version of the Standards, Options and Recommendations for nonmetastatic breast cancer (updated January 2001).《非转移性乳腺癌的标准、选择与建议》摘要版（2001年1月更新）
Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S17-31. doi: 10.1038/sj.bjc.6601081.
6
Summary of the Standards, Options and Recommendations for the management of patients with carcinoma of unknown primary site (2002).不明原发部位癌患者管理的标准、选择及建议总结（2002年）
Br J Cancer. 2003 Aug;89 Suppl 1(Suppl 1):S59-66. doi: 10.1038/sj.bjc.6601085.
7
Impact of prostate gland volume on cryoablation prostate-specific antigen outcomes.前列腺体积对冷冻消融前列腺特异性抗原结果的影响。
Urology. 2011 Apr;77(4):994-8. doi: 10.1016/j.urology.2010.08.010. Epub 2011 Feb 18.
8
Assessing and treating patients with increasing prostate specific antigen following radical prostatectomy.评估和治疗前列腺癌根治术后前列腺特异性抗原升高的患者。
J Urol. 2007 Sep;178(3 Pt 2):S20-4. doi: 10.1016/j.juro.2007.04.034. Epub 2007 Jul 20.
9
[How to treat a localized prostate cancer: irradiation, surgery or watchful waiting?].[如何治疗局限性前列腺癌：放疗、手术还是观察等待？]
Praxis (Bern 1994). 2005 Aug 24;94(34):1307-8. doi: 10.1024/0369-8394.94.34.1307.
10
Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.低睾酮水平与治疗前前列腺癌男性的不良预后因素有关。
BJU Int. 2012 Dec;110(11 Pt B):E541-6. doi: 10.1111/j.1464-410X.2012.11232.x. Epub 2012 May 15.

引用本文的文献

1
Inappropriate treatment of prostate cancer caused by heterophilic antibody interference.由嗜异性抗体干扰引起的前列腺癌不适当治疗。
Nat Clin Pract Urol. 2009 Mar;6(3):164-7. doi: 10.1038/ncpuro1317.

本文引用的文献

1
SOR: project methodology.SOR：项目方法学。
Br J Cancer. 2001 May;84 Suppl 2(Suppl 2):8-16. doi: 10.1054/bjoc.2000.1757.